RxDoctor Payments Data

Isaac Chambers, MD

Hematology & Oncology · Hays, KSNPI 1497168777

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.6% of the total across 304 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 57 manufacturers, the largest accounting for just 8.3% — the pattern of someone who eats at a lot of different presentations.

$5,825in general payments, 2019–2025

Across 304 payments — averaging $19.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$486
  • Novartis$458
  • Bristol Myers Squibb$364
  • AstraZeneca$343
  • Johnson & Johnson$281
  • Gilead$244
  • plus $4K from 51 others

What the payments were for

  • Food & beverage$5,62697%
  • Education$1983%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,825 in reported general payments places this provider in the 65th percentile of 97 hematology & oncology providers in Kansas.

See all hematology & oncology providers in Kansas

Medicare billing

Part B allowed, 2024
$127,165
Medicare patients
464
Services billed
1,698

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide33$484,069
BrukinsaZanubrutinib16$242,619
Abiraterone Acetate12$26,368
CreonLipase/Protease/Amylase13$12,675
Letrozole43$1,094
Anastrozole66$1,008
Tamoxifen Citrate42$584
Prochlorperazine Maleate45$522
Ondansetron Hcl23$401
Gabapentin33$351
Olanzapine23$306
Ondansetron OdtOndansetron14$286
Hydroxyurea21$270
Prednisone35$180
Levothyroxine Sodium18$103

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi$223$484,06933 claims
Beigene USA, Inc.Brukinsa$14$242,61916 claims
AbbVieCreon$155$12,67513 claims
Lilly USA, LLCOlanzapine$157$30623 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 97 hematology & oncology providers in Kansas.

Other hematology & oncology in Hays

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →